Spectrum Pharmaceuticals Inc

F:NTR

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of late-stage clinical and commercial products. The company is headquartered in Henderson, Nevada and currently employs 163 full-time employees. The firm's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.